Search academic texts

Information × Registration Number 0221U106423, 0118U003734 , R & D reports Title New methods of combined treatment patients with metastatic tumors of the abdominal cavity, retroperitoneum and small pelvis popup.stage_title Head Kolesnik Olena O., Доктор медичних наук Registration Date 06-12-2021 Organization National Cancer Institute popup.description2  The object of the study - 385 patients with malignant neoplasms of the abdominal cavity. The aim of the work is to improve the immediate and long-term results of combined treatment of patients with metastatic liver disease, colorectal cancer and malignant neoplasms of other sites by studying metabolic predictors of disease, developing a methodology for monitoring progression and improving existing surgical treatment algorithms. Research methods: clinical, laboratory, radiation, functional, pathomorphological, statistical. As a result of the analysis, it was shown that liver resections in patients with non-neuroendocrine and non-colorectal tumors are appropriate and safe. Long-term results are morphologically dependent. Selection for liver resection in patients with non-neuroendocrine and non-colorectal tumors should include assessment of the effectiveness of systemic preoperative treatment, patient status and analysis of the multidisciplinary team within a specialized surgical center. In retrospective analysis, it was found that atypical resections in CRC have satisfactory oncological results (5-year cumulative survival was 40 ± 5% and 33 ± 6%, respectively, for the group of atypical and anatomical resections, p = 0.03). It is scientifically proven that the pathological effect of ischemia-reperfusion has a negative impact on the survival of patients with CRC (median life expectancy for groups with and without MP was 24.03 ± 3.7 months and 37.8 ± 3.6 months, respectively). p = 0.05)), which requires further research. Operated liver ischemia may be a new factor in the oncological prognosis and an indicator of the quality of surgical treatment (median survival of patients was 25.61 ± 5.2 months, 24.07 ± 4.7 months, 14.03 ± 2.9 months and 27.87 ± 9.4 months. for groups A (IOP +), B (IOP-), B (IOP +) and A (IOP-) respectively (p = 0.03)). Product Description popup.authors Burlaka Anton A. Zakalska Christina А. Zubarev Nikolay G. Kvasivka Oleksandr O. Kopchak Kostantin V. Lisnyy Ivan І. Makhmudov Dmytro E. Sikachov Serhiy S. Yatsyna Oleksandr І. popup.nrat_date 2021-12-06 Close